In Silico Evaluation of Pharmacokinetic Optimization for Antimitogram-Based Clinical Trials

Area of Science:

• Oncology
• Pharmacology
• Biostatistics

Background:

• Antimitograms are in vitro tests using patient-derived cancer cells to assess chemotherapy efficacy.
• Optimizing cancer treatment through pharmacodynamic guidance is promising but faces technical challenges.
• Clinical validation of antimitograms requires refinement and demonstration of tangible benefits.

Purpose of the Study:

• To explore methods for validating antimitograms.
• To investigate complementing antimitograms with pharmacokinetic optimization.
• To model the synergistic impact of combined pharmacokinetic-pharmacodynamic optimization on progression-free survival (PFS).

Main Methods:

• Developed a generic computational model of advanced cancer incorporating pharmacokinetic-pharmacodynamic monitoring.
• Simulated various scenarios of pharmacokinetic and pharmacodynamic variability.
• Linked dosing schedules to PFS using validated modules to assess treatment efficacy.

Main Results:

• The model accurately recapitulated tumor dynamics and therapeutic drug monitoring efficacy.
• Combined pharmacokinetic and pharmacodynamic optimization synergistically increased simulated PFS.
• Simulated clinical trial sizes were reduced by 30%–90% with combined optimization.

Conclusions:

• Combining antimitograms with therapeutic drug monitoring offers synergistic benefits for optimizing cancer treatment.
• This integrated approach significantly reduces the number of patients required for clinical trials.
• Strategies with marginal benefits may be validated more efficiently through combined pharmacokinetic-pharmacodynamic optimization.